Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
- 4 August 2006
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 21 (4), 357-373
- https://doi.org/10.1177/0269881107075509
Abstract
People with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and hypertension than the general population. This results in an increased incidence of cardiovascuLar disease (CVD) and reduced Life expectancy, over and above that imposed by their mentaL illness through suicide. Several Levels of evidence from data Linkage analyses to clinical trials demonstrate that treatment-related metabolic disturbances are commonplace in this patient group, and that the use of certain second-generation antipsychotics may compound the risk of developing the metabolic syndrome and CVD. In addition, smoking, poor diet, reduced physical activity and alcohol or drug abuse are prevalent in people with schizophrenia and contribute to the overall CVD risk. Management and minimization of metaboLic risk factors are pertinent when providing optimal care to patients with schizophrenia. This review recommends a framework for the assessment, monitoring and management of patients with schizophrenia in the UK clinical setting.Keywords
This publication has 66 references indexed in Scilit:
- A 4-Fold Risk of Metabolic Syndrome in Patients With SchizophreniaBritish Journal of Psychology, 2005
- Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IVJournal of Human Hypertension, 2004
- Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan DatabaseJournal of Clinical Psychopharmacology, 2003
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- Schizophrenia and smoking: Evidence for a common neurobiological basis?American Journal of Medical Genetics, 2000
- The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trialInternational Journal of Psychiatry in Clinical Practice, 2000
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997
- Dr. Nemeroff and the Publishers ReplyBritish Journal of Psychology, 1997
- Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.Circulation, 1983